Prestige Consumer Healthcare (PBH) Competitors

Prestige Consumer Healthcare (NYSE:PBH) and Interparfums (NASDAQ:IPAR) are both mid-cap personal products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Which has better valuation & earnings, PBH or IPAR?

Prestige Consumer Healthcare has higher earnings, but lower revenue than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14B	2.91	$214.60M	$4.26	15.81
Interparfums	$1.45B	2.58	$164.36M	$4.99	23.35

Is PBH or IPAR more profitable?

Prestige Consumer Healthcare has a net margin of 19.02% compared to Interparfums' net margin of 11.03%. Interparfums' return on equity of 16.45% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	19.02%	12.69%	6.79%
Interparfums	11.03%	16.45%	11.14%

Which has more risk and volatility, PBH or IPAR?

Prestige Consumer Healthcare has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Does the media refer more to PBH or IPAR?

In the previous week, Interparfums had 3 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 11 mentions for Interparfums and 8 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.60 beat Interparfums' score of 0.80 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Interparfums	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend PBH or IPAR?

Prestige Consumer Healthcare presently has a consensus target price of $93.33, suggesting a potential upside of 38.55%. Interparfums has a consensus target price of $162.00, suggesting a potential upside of 39.02%. Given Interparfums' stronger consensus rating and higher probable upside, analysts plainly believe Interparfums is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Interparfums	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals hold more shares of PBH or IPAR?

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 55.6% of Interparfums shares are owned by institutional investors. 1.4% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 43.7% of Interparfums shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Interparfums beats Prestige Consumer Healthcare on 11 of the 16 factors compared between the two stocks.